Compare Plby Group Inc (PLBY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plby Group Inc vs Sana Biotechnology Inc — how do they compare? Plby Group Inc trades at $0.98 (market cap $118.21M), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Sana Biotechnology Inc is far larger — about 7.1× Plby Group Inc's market cap, and Plby Group Inc is more actively traded (919,783 versus 4,507,444). Which is the better fit depends on your goals — on Pluang, investors hold Plby Group Inc for 24 Days and Sana Biotechnology Inc for 23 Days on average.
| PLBY | SANA | |
|---|---|---|
Market Cap | $118.21M | $836.71M |
Volume | 919,783 | 4,507,444 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.71 | $5.92 |
52-Week Low | $0.99 | $2.68 |
Typical Hold Time | 24 Days | 23 Days |
Enterprise Value | $263.80M | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLBY Group trades at $0.98, down 3.66% today, with a bearish technical signal from moving averages and oscillators. The company shows improving fundamentals with revenue stabilizing around $121 million and narrowing losses from -$278M in 2022 to -$13M in 2025. Recent leadership appointments signal strategic growth initiatives, while analyst consensus remains strongly positive with 75% buy ratings.
The outlook suggests cautious optimism as PLBY transitions toward profitability, projected to reach net income of $283,000 in 2026. Key risks include high debt levels with 59.52% debt-to-asset ratio and persistent negative shareholder equity. The stock offers potential upside if turnaround execution succeeds, but remains vulnerable to operational challenges and market sentiment shifts.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
